Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
Only a quick read through but as I understand it SAVE are issuing a $900k convertible loan and assuming it converts will end up owning 25% of Lekoil which has taken a battering over the last few years but has raised some $260m in equity financing since 2013.
Sounds like a pretty crap position Lekoil find themselves in but a reasonable option purchase for Savannah which at that price they consider ‘immaterial’
I know it’s not exactly code to our strategy but does anyone know if Savannah has the potential / capacity / capability to ship LNG to Europe if the demand is there? Given world events Europe will clearly be looking for alternative gas supplies and I wondered if reserves in Nigeria could be sold, perhaps to pay down a chunk of net debt?
Even if there was a meeting room booked and even if the hotel let that slip the booking wouldn’t have the name of all the attendees. It would be either under the company name or one person’s name. No one makes a booking and starts listing all the attendees of the meeting
Weird statement here:
‘ In so far as the Company is aware, the percentage of the Company’s issued share capital that is not in public hands is 19.6%, which comprises the holding of Polygon Global Partners LLP and the directors’ beneficial holdings of 2.5%.’
Why are Polygon not considered ‘in public hands’ but Polar are? Does this imply more of an insider status for Polygon somehow? I’m not sure I understand the differential (note it’s published on a page just below the references to Polygon’s and Polar’s holdings).
That’s right. Looks like exactly the same share holding as before. No selling but higher total number of shares means their percentage has dropped
I’m really excited about SNG, hold a large amount and expect positive news very soon.
I just have to comment on this though as one of my new all time ‘favourite’ LSE views: ‘Polar may be selling to recalibrate in advance because they expect the news to be good and don’t want SNG to be too big a part of their portfolio’ :-)
I love this, I wish all investors would sell when they were confident of good news and worried about a share price doing too well. I’d be very happy to take such shares off their hands every time - at a suitable discount of course reflecting their distressed seller status because of their fear of their investment doing to well :-)
I just re-read the 15/12 RNS saying AffiDX had been tested with actual confirmed Omicron patient samples in Spain and it worked.
Four weeks later we get today’s RNS.
Hard to fathom what has changed in the meantime. I don’t get the impression from today that they’ve run hundreds of samples and concluded it’s statistically significantly much worse (although I could be wrong on that of course, but there have only been low hundreds of samples evaluated in total over a very long period so I doubt we’ve suddenly checked dramatically more not as part of any approval process)
Good interview. Nothing new in there from last week but presents the value proposition well.
Did anyone notice the slight chuckle from the presenter when he referred to the SP? He couldn’t believed where it was relative to the value in the business and the published forecasts / targets
Agreed. Some very bizarre commentary from someone who claims to be ‘invested’ in Savannah.
I generally try to ignore but the desperation this evening trying to talk this down is a bit much. Very obviously an ulterior motive at play.
Oops meant $ not £. Still not far off our market cap pre suspension
Real generation of £225m (revenue minus opex minus capex)
Looks incredibly healthy to me.
Plus promise of a dividend for the 2022 year (although smallish to begin with)
Only disappointment is not allowing PIs into the placing. It really would have been easy to use Primary Bid and give an allocation to existing investors only at the same price.
I guarantee if it wasn’t ready people will be working over the weekend until it is. This is so far from the kind of thing that tools get downed for at 5pm it’s not even a question.
I’d expected to see it this evening but if not I fully expect a 7am RNS on Monday. Hopefully they give us a day to read it though rather than readmission at 8am
I couldn’t maker the presentation today. Anyone know if there is a recording / playback available please?
To be fair I’ve been in a number of the same shares as Trek and rate him as an investor and he generally calls it as he sees it and gives good commentary, one of the better ones on LSE.
I disagree here and think AVCT still has far to run but abusing Trek is nuts, he is not the same as the blatant derampers that do come on here
If that’s right about Orient Gene the message needs to get out there loud and clear as there is a danger that otherwise the narrative becomes ‘oh yeah, the Innova ones weren’t that good and were banned by the FDA but that’s ok, we’ve stopped using them now and these Orient Gene tests are much better’. If Orient Gene are also now banned by the FDA then media, MPs, etc need to be made aware so they can challenge that narrative before it gets started
Analysis by the Economist - essentially the best data analysis you are likely to find published anywhere - shows 7-13m excess deaths worldwide since Covid started with a best estimate of over 10m deaths caused by Covid or associated complications (unable to access health care, etc).
Excess deaths in Britain have been repeatedly confirmed to be higher than the reported deaths, largely because there was so little testing at the beginning of the pandemic.
there was an increase in discharge rate at day 14 and a decrease in mortality at day 28. The time to negative reverse transcription polymerase chain reaction (RT-PCR) was shown to be significantly shortened in patients receiving IFN-ß, along with a lower nasopharyngeal viral load. Further, patients receiving IFN-ß had a less significant rise in IL-6. IFN-ß was shown to decrease intensive care unit (ICU) admission rate, the requirement of invasive ventilation in severe cases, and improve the survival rate compared to control groups. There were no severe adverse events reported. Our review found that patients who received early treatment with IFN-ß experienced significantly reduced length of hospitalization, mortality, ICU admission, and mechanical ventilation. A greater chance of clinical improvement and improved imaging studies was noted in patients who received IFN-ß
I always think it’s a good idea to be able to summarise the key reasons to buy in a succinct manner. I’ve had a go below, would be great to see anyone add to this:
- Actively in phase three trials in numerous countries around the world for SNG001
- In US Activ-2 programme at phase two with strong potential to move to phase three and possible EUA from the FDA
- Phase 2 data to date described as ‘best in the world’ amongst prospective Covid treatments
- In terms of scale suggested at 100k treatments per month. Competitive products sold at over $1k per treatment
All sounds pretty compelling. What would you add to this?